Long Focus Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Long Focus Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-327,692	Closed	-$108K	–	122
2023 Q1	$108K	Hold	327,692	–	–	0.01%	109
2022 Q4	$236K	Hold	327,692	–	–	0.02%	99
2022 Q3	$393K	Hold	327,692	–	–	0.04%	89
2022 Q2	$390K	Buy	327,692 +87,930	+37%	+$133K	0.04%	92
2022 Q1	$518K	Buy	+239,762	New	+$390K	0.07%	85

Other funds holding BLCM

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

PGAM

Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return

Long Focus Capital Management's BLCM Position: Q2 2023 in Review

Long Focus Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 327,692 shares — an estimated $108K sold.

Long Focus Capital Management first reported a position in BLCM in Q1 2022 and held it in 5 quarters. The position peaked at $518K in Q1 2022. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.

Long Focus Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Long Focus Capital Management sold 327,692 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $108K.
Long Focus Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2022 and held it in 5 quarters.
Long Focus Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $518K in Q1 2022.
4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.

Based on Long Focus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.